Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, November 19, 2016

Communicating with Your MS Healthcare Provider begins with the right questions to ask


                                                                  
  

Click here to receive MS news via e-mail


Having the right tool in front of you (or with you) may be all that is needed to effectively communicate with your Neurology Healthcare provider.

The communication tool seen below (page 1 showing), is a document tool that will make navigating through your MS neurology appointments more simplified.




Having this two-document (print from here) completed before your next visit then remembering to bring it with you are the first two steps.

Then giving the completed document to your neurology healthcare team is the third step.

Reviewing this information with your MS neurologist or MS nurse practitioner is needed next. 
Then having that person communicate with you about all the notes you made on this two page document will help you best, to communicate with your MS healthcare team.

Yes, having and using this two page document would Help You (the MS Patient), to effectively communicate with your MS Healthcare provider.

To obtain this 2-page document communication document, click here.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


To learn more from MS Views and News, be registered-with, or simply click here. 

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
Providing educational information, resources and services for those affected by MS


Friday, November 18, 2016

OVER-ACTIVE Bladder issues


                                                                  
  

Click here to receive MS news via e-mail


Products to Use

The Real Deal on Your Bladder (Myths and Facts)
Stop the Stream
Herbal Remedies
How do Kegels Help
Tips for Better Sex and Sleep
Why you need to go so often?





       MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis                            Providing educational information, resources and services for those affected by MS

National Caregivers Awareness Month – a time to recognize the important role that caregivers and support partners play in chronic conditions like MS


                                                                  
  

Click here to receive MS news via e-mail



November is National Caregivers Awareness Month – a time to recognize the important role that caregivers and support partners play in chronic conditions like MS.

To recognize the important role that caregivers can play, we wanted to share the story of Jesse, a support partner who cares for his wife with MS. In this newsworthy story from Genentech, Jesse shares their journey about how MS impacts their daily lives and how they cope with the unpredictability of the disease together.

Jesse’s story also highlights results from a new national survey Genentech conducted, the MS Mindset Survey, to better understand the everyday impact of MS. MS Mindset showed how the unpredictable nature of MS can impact the day-to-day lives of people living with MS and their loved ones as well as highlighting different areas on need in daily life. I’ve also attached more information about the survey for your background.

To Read Jesse's story, click here


Please share this story with others - thank you 




MS Views and News
Providing educational information, resources and services for those affected by MS

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis



Monday, November 14, 2016

Canadian Firm begins training people who will use it's Keeogo walking assistive device


                                                                  
  

Click here to receive MS news via e-mail

b-temialogo



B-Temia announced the launch of its “b-Klinic Mobility” business unit, offering clinical services, information, training, and ongoing support to patients and healthcare professionals who use the company’s Keeogo walking assistive device.

Keeogo is B-Temia’s first product in the class of dermoskeletons, designed to assist persons with mobility-related challenges that limit their ability to participate in daily activities, such as walking, climbing or descending stairs, sitting down, or standing up.
The device is for use in a variety of degenerative conditions that limit mobility, including multiple sclerosis, knee/hip osteoarthritis, Parkinson’s disease, stroke, and spinal cord injury.
Commercially available for purchase or rental in Canada, Keeogo is under investigation in a multicenter clinical trial (NCT02904382) aimed at obtaining the U.S. Food and Drug Administration (FDA) clearance needed to enter the U.S. market.
Keeogo utilizes sensors at the knee and hip joints to read a person’s body position and desired movement, and to provide the needed assistance to help complete that action. Keeogo does not initiate movement, but waits for the wearer’s lead and first indication, then assists in executing it — like pushing up when the wearer begins to stand up, or slowly supporting a person who is starting to sit down. For more information on how Keeogo works click here.
Read more/See more - here



MS Views and News
Providing educational information, resources and services for those affected by MS

Development of an MS medication (MT1303) that showed promising results, has been discontinued


                                                                  
  

Click here to receive MS news via e-mail



Amiselimod (former MT-1303) is an investigational sphingosine 1-phosphate (S1P) receptor modulator that was in development by Biogen for people with relapsing-remitting multiple sclerosis RRMS, inflammatory bowel disease, and other autoimmune conditions.
S1P receptor modulators interfere with S1P signaling. They block lymphocytes (immune cells) from receiving exit signals inside the lymph nodes, which keeps the immune cells trapped inside the node. The result is a reduction of circulating T- and B-cells leading to anti-inflammatory activity because it stops the migration of certain immune cells to the actual sites of inflammation.
A Phase 2 study (NCT01742052) of amiselimod in patients with RRMS was completed in September with successful and promising results. Amiselimod (0.2 mg and 0.4 mg) significantly reduced the total number of brain lesions and produced a safety and effectiveness profile that suggested it should be furthered studied as  a new potential treatment for people with RRMS.
Although the trial results showed positive results, Biogen has discontinued development of amiselimod without explanation, according to a press release.
Read complete story here




MS Views and News
Providing educational information, resources and services for those affected by MS

Sunday, November 13, 2016

Remyelinating Monoclonal Antibody for Treatment of MS


                                                                  
  

Click here to receive MS news via e-mail



rHIgM22 is a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). A second Phase 1 trial in people with MS is currently recruiting patients experiencing an acute relapse. We expect to complete this trial in the first half of 2017.
In April 2015, Acorda presented data from its first Phase 1 clinical trial of rHIgM22. Safety data showed it was well-tolerated in each of the five tested doses, supporting additional clinical development. In addition, testing detected rHIgM22 in cerebrospinal fluid, indicating the drug’s access to the central nervous system. These data were presented at the 67th American Academy of Neurology Annual Meeting.



MS Views and News
Providing educational information, resources and services for those affected by MS

Emiratis in Abu Dhabi living with MS ‘more than double global average’


                                                                  
  

Click here to receive MS news via e-mail




  • MS unpleasant but manageable


ABU DHABI // The number of Emiratis in the capital living with multiple sclerosis (MS) is more than twice the global ­average, a study revealed.
The autoimmune disorder affects 64.44 per 100,000 people in Abu Dhabi, while the World Health Organisation estimated average global prevalence was 30 per 100,000. Low vitamin D levels, smoking and genetic factors may be causes.
"The Abu Dhabi Emirati population has one of the highest, most reliable prevalence rates on the Arab peninsula," it was reported in the How Global MS Prevalence is Changing: A Retrospective Chart Review in the United Arab Emirates study.

    The report was carried out by Johns Hopkins University in conjunction with Tawam Hospital.
    Traditionally, the prevalence of MS in the Arab world has been thought to be low," said Nicoline Schiess, assistant professor of neurology at Johns Hopkins who worked on the study.

      "However, as more studies are done in this region and there is more knowledge and awareness of the disease and the access to MRIs are increased, the data is starting to show that the difference in prevalence of MS ­between the Arab world and parts of the United States and western Europe are not as great as previously thought.












      MS Views and News
      Providing educational information, resources and services for those affected by MS





      Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016


                                                                        
        

      Click here to receive MS news via e-mail


      November 13th, 2016 - WiseGuyReports

      Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016
      Summary
      Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2016, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline landscape.
      Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS). In RRMS, there are clear episodes of inflammatory activity (relapses). During a period of acute inflammation, old symptoms may worsen and new symptoms may appear. A relapse is when active inflammation, and the resulting symptoms, last more than 24 hours. Symptoms include tingling or numbness, double vision, fatigue, urinary urgency and weakness. Treatment includes corticosteroids and immunoglobulin therapy.
      Report Highlights
      Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
      The Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 18, 1, 6 and 1 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively for Relapsing Remitting Multiple Sclerosis (RRMS).
      Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
      Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
      Scope






      MS Views and News
      Providing educational information, resources and services for those affected by MS





      More States Pass Medicinal, Recreational Marijuana Initiatives in 2016 Election


                                                                        
        

      Click here to receive MS news via e-mail



      primary care, family medicine, internal medicine, hospital medicine, pain management, medical marijuana, cannabis, weed, pot, drugs, election 2016, vote



      Twenty-five states and the District of Columbia already have legalized medicinal marijuana and only Colorado, Washington, Oregon, Alaska, and DC have legalized it for recreational use. While all states differ on which health conditions warrant a pot prescription, the common ones are chronic pain, glaucoma, seizures, and the human immunodeficiency virus (HIV). - 



      On November 8, four states voted on initiatives for medicinal marijuana and five states voted for recreational use. Here’s what happened.

      Voters in all four states passed initiatives in favor of medicinal marijuana:

      • Arkansas: 53% voted yes
            -  Passed for 17 medical conditions
      • Florida: 71% voted yes
            -  Passed for debilitating medical conditions as determined by a doctor
      • Montana: 57% voted yes
            -  Loosened the restrictions on conditions and number of patients
      • North Dakota: 64% voted yes

      Only California, Massachusetts, and Nevada said yes to recreational use. Votes in Maine, however, are still coming in and the results are incredibly close, but “yes” is winning at the moment. 

      - See more 





      MS Views and News
      Providing educational information, resources and services for those affected by MS





      Alemtuzumab Better than Interferon in Multiple Sclerosis -


                                                                        
        

      Click here to receive MS news via e-mail


      Alemtuzumab provided more benefits to patients with relapsing remitting multiple sclerosis (RRMS) who had poor response to other therapies than subcutaneous interferon-B-1a (SC IFN-B-1a) provided, according to the results of a recent study. Conducted by Gavin Giovannoni, MD, PhD, of Queen Mary University of London, and colleagues, the study was published in the journal Neurology on October 12, 2016.   





      The authors begin by discussing the fact that limiting disability is an important part of caring for patients with MS, but that interest is increasing in not only limiting disability but in helping patients with disability improve. They say, “Interest is growing in aiming for confirmed disability improvement (CDI), a higher standard for therapeutic efficacy than merely slowing disability accumulation.” In pursuit of that goal, the researchers say the aim of the present study was “to characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing remitting multiple sclerosis with inadequate response to prior therapy.” 

      - See more 









      MS Views and News
      Providing educational information, resources and services for those affected by MS





      The goal of rehabilitation is to improve and maintain function


                                                                        
        

      Click here to receive MS news via e-mail

      Improving and Maintaining Function
        It is an essential component of comprehensive MS care. From the time of diagnosis onward, rehabilitation specialists provide education and strategies designed to promote good health and overall conditioning, reduce fatigue, and help you feel and function at your best — at home and at work.

      If symptoms begin to interfere with everyday activities, rehabilitation can address these problems — with mobility, dressing and personal care, driving, functioning at home and work, and participation in leisure activities. Rehabilitation experts can also provide evaluation and treatment of speech and swallowing difficulties, and problems with thinking and memory.
      Contact the Society online or call 1-800-344-4867 for more information or a referral to any rehabilitation specialist or other healthcare provider.

      The rehabilitation team

      Physical therapy

      Physical therapists (PT) evaluate and address the body’s ability to move and function, with particular emphasis on walking and mobility, strength, balance, posture, fatigue and pain. Physical therapy might include an exercise program, gait training and training in the use of mobility aids (canes, crutches, scooters and wheelchairs) and other assistive devices. The goal is to promote safety, achieve and maintain optimal functioning, and prevent unnecessary complications such as de-conditioning, muscle weakness from lack of mobility and muscle contractures related to spasticity. Physical therapy can also include pelvic floor exercises which may help address urinary/bladder issues.

      Occupational therapy

      The goal of occupational therapy (OT) is to enhance independence, productivity and safety in all activities related to personal care, leisure activities and employment. OTs provide training in energy conservation techniques and the use of adaptive tools and devices to simplify tasks at home and in the office. They recommend strategic modifications to the home and workplace to ensure accessibility and convenience. Occupational therapists also evaluate and treat problems with thinking and memory.

      Cognitive rehabilitation

      Neuropsychologists — as well as many OTs and SLPs — evaluate and treat changes in a person’s ability to think, reason, concentrate or remember. While these professionals use different evaluation and treatment strategies, they share the common goal of helping people function optimally if cognitive changes are experienced.

      Vocational rehabilitation

      State vocational rehabilitation programs offer job readiness training, job coaching, job placement assistance, mobility training and assistive technology assessments — with the goal of helping people maintain their current employment or find new employment that accommodates their needs.

      Speech-language pathology

      The speech-language pathologist (SLP) evaluates and treats problems with speech and/or swallowing— both of which can result from damage in the central nervous system that reduces control of the muscles used in these important functions. The goal of therapy is to enhance ease and clarity of communication as well as promote safe swallowing and overall health. Some SLPs also evaluate and treat problems with thinking and memory.

      Resources

      American Physical Therapy Association
      Provides an online search tool to locate APTA member physical therapists.
      American Academy of Physical Medicine and Rehabilitation
      Provides an online search tool to locate physiatrists.
      American Academy of Clinical Neuropsychology
      Provides an online directory of psychologists who are board-certified in clinical neuropsychology.
      American Speech-Language-Hearing Association
      Provides an online search tool for speech-language pathologists.
      Article source



      MS Views and News
      Providing educational information, resources and services for those affected by MS
      Be an MS Champion, by helping to provide the Empowering knowledge we share. 
      To receive MS news and information, Opt-in here

      Vitamin Supplements for Neurological Disorders


                                                                        
        

      Click here to receive MS news via e-mail



      It is not uncommon for neurology patients to inquire about vitamins and natural supplements for the treatment of serious neurological conditions. While nutritional factors have not been shown to have a causative relationship to most neurological disorders that are currently considered incurable, such as motor neuron disease and degenerative disease of the nervous system, it turns out that vitamin and nutritional deficiencies, as well as nutritional toxicities, have been detected among some patients who have neuropathy.



      The use of supplements to treat neurological illness 
      Overall, even when some nutritional deficits have been associated with neurological disease, supplements have not been shown to provide the idyllic holistic cure that many patients are searching for. Yet, there are some clinical settings in which nutritional supplementation can play a real and valuable role in the management of neurological disease. 
      Nutritional deficiencies in neuropathy 
      The most substantive association between nutritional issues and neurological disease is seen in neuropathy. A study from Weil Cornell Medical Center in New York showed that approximately 1/4 of patients with neuropathy had nutritional abnormalities. The most common abnormalities detected were elevated mercury or pyridoxal phosphate levels. Deficiencies such as vitamins B1, B6, and B12 were also observed among patients who were diagnosed with neuropathy. 

      The role of the neurologist in communicating the benefits and limitations of nutritional supplements
      To read complete article, click here




      MS Views and News
      Providing educational information, resources and services for those affected by MS